GLP-1 Drugs and Sexual Function Evidence

A July 2026 letter in the Journal of the American Academy of Dermatology argues, in its title, that sexual function is missing from the adverse-effect map of GLP-1 receptor agonists in dermatology^[1]. PubMed classifies the item as a letter and provides no abstract. That record supports the title, authorship, journal date and publication type. It does not expose the authors' examples, methods or conclusions, so none should be invented. The broader evidence remains mixed and mostly observational.

What the letter record can and cannot tell us

The available PubMed entry lists a 3 July 2026 publication date, the article title and a digital object identifier. It labels the publication a letter^[1]. There is no abstract, patient count, adverse-event table or stated recommendation in that record. The title indicates a concern about what clinicians measure. It does not prove that semaglutide, tirzepatide or another GLP-1 medicine causes a particular sexual problem.

That distinction is the whole readout. A commentary can identify an overlooked question without supplying new outcome data. To understand why the question remains unsettled, we have to examine separate primary records. Those records are background evidence and should not be attributed to the letter's unnamed argument.

One large observational study found a modest positive association

A 2026 target trial emulation used electronic health records from a US health system. It compared adult men with type 2 diabetes who started a GLP-1 receptor agonist with men who started a DPP-4 inhibitor between 2019 and 2024. After weighting, the analysis included 4,910 GLP-1 initiators and 5,524 comparator initiators^[2]. Erectile dysfunction was identified through diagnosis codes rather than a purpose-built sexual-function questionnaire.

The recorded incidence rates were 35.2 and 28.0 per 1,000 person-years, respectively. The adjusted hazard ratio was 1.26 (95% confidence interval 1.08 to 1.46)^[2]. Yet the association weakened and lost statistical significance after negative-control outcome calibration. The authors explicitly said residual or selection bias may explain the finding and that the observational design cannot establish causation.

Other records point in different directions

A separate retrospective study compared tirzepatide with sitagliptin, injectable semaglutide and dulaglutide in men with type 2 diabetes and no prior erectile dysfunction. Its outcome combined a diagnosis code with prescription of a PDE-5 inhibitor. Tirzepatide was associated with lower event risk in all three matched comparisons, including a risk ratio of 0.67 versus injectable semaglutide^[4]. The authors called for randomized trials, which is appropriate because treatment selection and weight change can confound retrospective comparisons.

A 2025 case report described anorgasmia after initiation of a GLP-1 agonist and proposed several possible mechanisms^[3]. A single case can document timing and clinical observations, but it cannot estimate prevalence or isolate a drug effect from medical, hormonal and psychosocial factors. The proposed mechanisms remain hypotheses. They should not be presented as established pathways.

Why sexual-function outcomes are unusually hard to interpret

Obesity and type 2 diabetes can themselves affect vascular health, hormones, mood and sexual function. Weight loss or improved glucose control may improve some of those pathways. Treatment side effects, relationship factors, depression and other medicines may move outcomes in the opposite direction. A routine diagnosis code captures only a small part of that picture, and people may never raise sexual symptoms during a short visit.

The studies also ask different questions. The target trial emulation examined GLP-1 drugs as a class against DPP-4 inhibitors^[2]. The tirzepatide analysis compared named drugs and used a composite outcome^[4]. The case report focused on orgasm rather than erectile function^[3]. Those outcomes cannot be collapsed into one claim about libido or sexual health.

What better evidence would look like

Future trials should specify sexual function before enrolment and use validated measures at baseline and follow-up. They should report outcomes by sex, drug, dose and indication while tracking weight change, glycaemic control, mood and relevant concomitant medicines. Attrition matters too, since people who stop treatment after side effects may disappear from later questionnaires. Those design choices would help distinguish treatment effects from the conditions being treated.

Absolute numbers should accompany relative estimates. Researchers also need enough follow-up to separate a temporary change during rapid weight loss from a persistent problem. Preplanned analyses could then test whether any association differs between obesity treatment and diabetes care without turning a chance subgroup finding into a conclusion. Until that work exists, product comparisons remain provisional.

For now, the evidence supports a conversation rather than a verdict. A new sexual symptom after starting or changing a medicine deserves clinical review, especially when it affects quality of life. It does not follow that the medicine caused the symptom, nor that someone should stop it without discussing the risks and alternatives with the prescriber. Our semaglutide safety notes place this narrow question alongside better-established adverse effects.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.